HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by SFIKAKIS, A. P. Articles by VARONOS, D. D. Search for Related Content PubMed PubMed Citation Articles by SFIKAKIS, A. P. Articles by VARONOS, D. D.

Metyrapone (2-methyl-1,2-bis-(3-pyridyl)-1-propanone, SU-4885) when administered to normal women decreases urinary oestrogen excretion (Földes, Koref, Fehér & Steczek, 1964; Sfikakis, Ikkos & Diamandopoulos, 1967) whereas in women with the polycystic ovary syndrome urinary oestrogen excretion is increased (Sfikakis et al. 1967). On the other hand, metyrapone inhibits oestrogen production from androgen precursors in the isolated organ (Giles & Griffiths, 1964; Koref, Steczek, Fehér & Földes, 1966) as well as oestrogen production in the intact animal (Matsumoto, Kotoh, Miyata & Kurachi, 1965).

In order to study further the action of metyrapone on oestrogen production in vivo it was thought that the uterus of female rats after the administration of dehydroepiandrosterone (DHA) would be a suitable model, in view of the oestrogen-like effect of DHA on the uterus of immature female rats described by Harper (1969).

The study included 43 prepubertal female rats (Wistar, aged 29–35 days on day of autopsy) and 46